blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3165922

EP3165922 - A METHOD FOR QUANTIFYING THERAPEUTIC ANTIBODIES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  23.04.2021
Database last updated on 19.10.2024
FormerThe patent has been granted
Status updated on  15.05.2020
FormerGrant of patent is intended
Status updated on  27.02.2020
FormerExamination is in progress
Status updated on  10.08.2018
FormerRequest for examination was made
Status updated on  17.11.2017
FormerThe application has been published
Status updated on  07.04.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Promise Proteomics
7 Parvis Louis Néel
Bht 52A
CS 20050
38040 Grenoble cedex 9 / FR
[2019/36]
Former [2017/19]For all designated states
Promise Advanced Proteomics
7 Parvis Louis Neel
CS20050
38040 Grenoble Cedex 9 / FR
Inventor(s)01 / LEBERT, Dorothée
32 chemin des olagnères
38450 Le Gua / FR
02 / PICARD, Guillaume
90 chemin de Culaz
74130 Mont-Saxonnex / FR
 [2017/19]
Representative(s)Cabinet Nony
11 rue Saint-Georges
75009 Paris / FR
[N/P]
Former [2017/19]Nony
11 rue Saint-Georges
75009 Paris / FR
Application number, filing date15306767.306.11.2015
[2017/19]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3165922
Date:10.05.2017
Language:EN
[2017/19]
Type: B1 Patent specification 
No.:EP3165922
Date:17.06.2020
Language:EN
[2020/25]
Search report(s)(Supplementary) European search report - dispatched on:EP29.04.2016
ClassificationIPC:G01N33/50, G01N33/68
[2017/19]
CPC:
G01N33/6857 (EP,US); C12N9/6491 (EP,US); G01N33/502 (EP,US);
G01N33/6848 (EP,US); C12Y304/24003 (EP,US); C12Y304/24023 (EP,US);
C12Y304/24024 (EP,US); C12Y304/24035 (EP,US); G01N2458/15 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/51]
Former [2017/19]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:VERFAHREN ZUR QUANTIFIZIERUNG VON THERAPEUTISCHEN ANTIKÖRPERN[2017/19]
English:A METHOD FOR QUANTIFYING THERAPEUTIC ANTIBODIES[2017/19]
French:PROCÉDÉ PERMETTANT DE QUANTIFIER DES ANTICORPS THÉRAPEUTIQUES[2017/19]
Examination procedure06.11.2015Date on which the examining division has become responsible
06.11.2017Amendment by applicant (claims and/or description)
10.11.2017Examination requested  [2017/51]
08.08.2018Despatch of a communication from the examining division (Time limit: M04)
18.10.2018Reply to a communication from the examining division
17.12.2018Despatch of a communication from the examining division (Time limit: M04)
23.04.2019Reply to a communication from the examining division
30.01.2020Cancellation of oral proceeding that was planned for 12.02.2020
12.02.2020Date of oral proceedings (cancelled)
28.02.2020Communication of intention to grant the patent
12.05.2020Fee for grant paid
12.05.2020Fee for publishing/printing paid
12.05.2020Receipt of the translation of the claim(s)
Opposition(s)18.03.2021No opposition filed within time limit [2021/21]
Fees paidRenewal fee
30.11.2017Renewal fee patent year 03
30.11.2018Renewal fee patent year 04
02.12.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU06.11.2015
AL17.06.2020
AT17.06.2020
CY17.06.2020
CZ17.06.2020
DK17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
MC17.06.2020
MK17.06.2020
MT17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SI17.06.2020
SK17.06.2020
SM17.06.2020
TR17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
IE06.11.2020
LU06.11.2020
CH30.11.2020
LI30.11.2020
[2022/32]
Former [2022/27]HU06.11.2015
AL17.06.2020
AT17.06.2020
CY17.06.2020
CZ17.06.2020
DK17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
MC17.06.2020
MT17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SI17.06.2020
SK17.06.2020
SM17.06.2020
TR17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
IE06.11.2020
LU06.11.2020
CH30.11.2020
LI30.11.2020
Former [2021/46]AL17.06.2020
AT17.06.2020
CZ17.06.2020
DK17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
MC17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SI17.06.2020
SK17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
IE06.11.2020
LU06.11.2020
CH30.11.2020
LI30.11.2020
Former [2021/37]AL17.06.2020
AT17.06.2020
CZ17.06.2020
DK17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
MC17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SI17.06.2020
SK17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
LU06.11.2020
CH30.11.2020
LI30.11.2020
Former [2021/33]AL17.06.2020
AT17.06.2020
CZ17.06.2020
DK17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
MC17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SI17.06.2020
SK17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
LU06.11.2020
Former [2021/31]AL17.06.2020
AT17.06.2020
CZ17.06.2020
DK17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
MC17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SI17.06.2020
SK17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
Former [2021/24]AL17.06.2020
AT17.06.2020
CZ17.06.2020
DK17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SI17.06.2020
SK17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
Former [2021/21]AL17.06.2020
AT17.06.2020
CZ17.06.2020
DK17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SK17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
Former [2021/10]AL17.06.2020
AT17.06.2020
CZ17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SK17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
Former [2021/09]AL17.06.2020
AT17.06.2020
CZ17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
PT19.10.2020
Former [2021/04]AL17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
RS17.06.2020
SE17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
Former [2021/01]FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
RS17.06.2020
SE17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
Former [2020/51]FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
RS17.06.2020
SE17.06.2020
NO17.09.2020
GR18.09.2020
Former [2020/50]FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
SE17.06.2020
NO17.09.2020
GR18.09.2020
Former [2020/48]FI17.06.2020
LT17.06.2020
SE17.06.2020
NO17.09.2020
Former [2020/47]LT17.06.2020
NO17.09.2020
Documents cited:Search[A]US2012177568  (WILLIAMS JOHN C [US], et al) [A] 1-15* the whole document *;
 [A]EP2676137  (NESTEC SA [CH]) [A] 1,2,4-15 * the whole document *;
 [I]  - LEBERT DOROTHEE ET AL, "Absolute and multiplex quantification of antibodies in serum using PSAQ (TM) standards and LC-MS/MS", BIOANALYSIS, FUTURE SCIENCE, LONDON, UK, (20150421), vol. 7, no. 10, doi:10.4155/BIO.15.56, ISSN 1757-6180, pages 1237 - 1251, XP009188595 [I] 1-15 * abstract, pg 1238-1249. *

DOI:   http://dx.doi.org/10.4155/bio.15.56
 [I]  - OLIVIER HEUDI ET AL, "Towards Absolute Quantification of Therapeutic Monoclonal Antibody in Serum by LC-MS/MS Using Isotope-Labeled Antibody Standard and Protein Cleavage Isotope Dilution Mass Spectrometry", ANALYTICAL CHEMISTRY, (20080601), vol. 80, no. 11, doi:10.1021/ac800205s, ISSN 0003-2700, pages 4200 - 4207, XP055031993 [I] 1-15 * abstract, pg 4200-4207. *

DOI:   http://dx.doi.org/10.1021/ac800205s
 [I]  - PENG XIAOYUN ET AL, "Development and Validation of LC-MS/MS Method for the Quantitation of Infliximab in Human Serum", CHROMATOGRAPHIA, VIEWEG UND TEUBNER VERLAG, DE, vol. 78, no. 7, doi:10.1007/S10337-015-2866-2, ISSN 0009-5893, (20150228), pages 521 - 531, (20150228), XP035474329 [I] 1,2,4-15 * abstract, pg 522-530. *

DOI:   http://dx.doi.org/10.1007/s10337-015-2866-2
 [I]  - KEYANG XU ET AL, "A multiplexed hybrid LC-MS/MS pharmacokinetic assay to measure two co-administered monoclonal antibodies in a clinical study", BIOANALYSIS, FUTURE SCIENCE, LONDON, UK, (20140101), vol. 6, no. 13, ISSN 1757-6180, pages 1781 - 1794, XP009188591 [I] 1-15 * pg1781-1792. *
 [I]  - QIAN ZHANG ET AL, "Generic Automated Method for Liquid Chromatography-Multiple Reaction Monitoring Mass Spectrometry Based Monoclonal Antibody Quantitation for Preclinical Pharmacokinetic Studies", ANALYTICAL CHEMISTRY, US, (20140902), vol. 86, no. 17, doi:10.1021/ac5019827, ISSN 0003-2700, pages 8776 - 8784, XP055252059 [I] 1-15 * pg 8776-8783. *

DOI:   http://dx.doi.org/10.1021/ac5019827
 [I]  - MEKHSSIAN KEVORK ET AL, "Application of high-resolution MS in the quantification of a therapeutic monoclonal antibody in human plasma", BIOANALYSIS, FUTURE SCIENCE, LONDON, UK, (20140101), vol. 6, no. 13, doi:10.4155/BIO.14.111, ISSN 1757-6180, pages 1767 - 1779, XP009188594 [I] 1,3-15 * pg 1767-1777. *

DOI:   http://dx.doi.org/10.4155/bio.14.111
by applicant   - WU ET AL., RAPID COMMUN MASS SPECTROM., (2011), vol. 25, pages 281 - 90
    - KAMIIE ET AL., PHARMACEUTICAL RESEARCH, (2008), vol. 25, no. 6, pages 1469 - 1483
    - LAWLESS ET AL., OMICS, (201209), vol. 16, no. 9
    - TAMERIUS ET AL., INT J CANCER, (1975), vol. 16, pages 456 - 464
    - TAMERIUS ET AL., J IMMUNOL, (1976), vol. 116, pages 724 - 730
    - REICHERT ET AL., MABS, (2010), vol. 2, pages 84 - 100
    - STROHL ET AL., CURR OPINION BIOTECHNOL, (2009), vol. 20, pages 685 - 691
    - BREZSKI ET AL., MABS, (2010), vol. 2, no. 3, pages 212 - 220
    - VINCENT A. FUSARO; D. R. MANI; JILL P. MESIROV; STEVEN A. CARR, NATURE BIOTECHNOLOGY, (2009), vol. 27, pages 190 - 198
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.